Secondary Hyperparathyroidism (SHPT) Secondary hyperparathyroidism (SHPT) occurs when the parathyroid glands become enlarged and release too much PTH, causing a high blood level of PTH. Parathyroid hormone controls the level of calcium is in blood and within bones. Secondary hyperparathyroidism is commonly associated with vitamin D deficiency and chronic kidney disease (CKD). The kidney cannot convert vitamin D into the physiologically active 1,25- cholecalciferol. Reduced intestinal absorption of calcium resulting in a low serum calcium and elevated phosphate due to renal failure to excrete phosphate increases secretion of parathyroid hormone. Prolonged stimulation results in parathyroid hyperplasia. SHPT also occurs in vitamin D- deficient rickets, malabsorption, and pseudohypoparathyroidism. DelveInsight's "Secondary Hyperparathyroidism - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Secondary Hyperparathyroidism, historical and forecasted epidemiology as well as the Secondary Hyperparathyroidism market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Geography Covered The United States EU5 (Germany, France, Italy, Spain, and the United Kingdom) Japan Study Period:2017-2030 Request request/secondary-hyperparathyroidism-market Secondary Hyperparathyroidism Disease Understanding and Treatment Algorithm Secondary hyperparathyroidism can cause bone disease. It can also cause calcium to build up in tissues and organs such as the heart and blood vessels. The bones are in a constant state of change. There are cells that build new bone and cells that remove old bone. This process is known as “bone turnover.” If one has secondary hyperparathyroidism, bone turnover is high. This means that the cells that remove bone are working more quickly than the cells that build new bone, causing your bones to become weak and brittle. This can increase your chances of having bone pain and fractures. The DelveInsight Secondary Hyperparathyroidism market report gives a thorough understanding of the Secondary Hyperparathyroidism by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment. Diagnosis For diagnosis of SHPT, Evaluation in SHPT consists of monitoring of lab values of PTH, calcium, phosphorus, vitamin D levels, and renal function. This segment of the report covers the detailed diagnostic methods or tests for Secondary Hyperparathyroidism. Treatment for sample pages: https://www.delveinsight.com/sample-
There are several treatments for secondary hyperparathyroidism including drugs, surgery (an operation), and controlling your blood phosphorus levels. o Drugs: There are three types of drugs for secondary hyperparathyroidism—vitamin D supplements, active vitamin D (or vitamin D analogs) and cinacalcet. o Surgery: Parathyroidectomy is an operation that removes the parathyroid glands. This operation is only for very severe cases of hyperparathyroidism that cannot be managed with medicine. o Controlling Your Blood Phosphorus Levels: Since high blood phosphorus levels increase the release of PTH, it is important to keep your blood phosphorus in normal range using diet and phosphate binders. It covers the details of conventional and current medical therapies available in the Secondary Hyperparathyroidism market for the treatment of the condition. It also provides Secondary Hyperparathyroidism treatment algorithms and guidelines in the United States, Europe, and Japan. Secondary Hyperparathyroidism Epidemiology Secondary hyperparathyroidism is common among patients with vitamin D deficiency and chronic kidney disease. It has been observed that medical therapy does not work in up to 25% of patients and surgery is sometimes necessary. Since about half, the world population is vitamin D deficient, and about 1/7 have CKD, it is important to understand the condition in depth. The Secondary Hyperparathyroidism epidemiology division provide insights about historical and current Secondary Hyperparathyroidismpatient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. Download sample pages: https://www.delveinsight.com/sample- request/secondary-hyperparathyroidism-market Secondary Hyperparathyroidism Drug Chapters The current pipeline for Secondary Hyperparathyroidism has many significant products. The dynamics of Secondary Hyperparathyroidism market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, incremental healthcare spending across the world, and also due to the expected launch of many therapies during the forecast period. Key players such as Sanwa Kagaku Kenkyusho, TaiRx and many others are developing therapies for the treatment of patients with Secondary Hyperparathyroidism. Expected launch of emerging therapies such as SK-1403 (Sanwa Kagaku Kenkyusho), TRX 711 (TaiRx), CYP24A1 inhibitors and CTAP101 (calcifediol) ER Capsules (OPKO Health) and other compelling treatments, are expected to increase the market size of Secondary Hyperparathyroidism in upcoming years. Drug chapter segment of the Secondary Hyperparathyroidism report encloses the detailed analysis of Secondary Hyperparathyroidism marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Secondary Hyperparathyroidismclinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. Secondary Hyperparathyroidism Market Outlook
Management in Secondary Hyperparathyroidism (SHPT) targets abnormal phosphocalcic metabolism. Maintaining the serum calcium and phosphorus levels within the normal range along with control of PTH and vitamin D levels is the key in management and secondary hyperparathyroidism. The U.S. National Kidney Foundation (NKF) proposed the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines and established targets for biomarkers (calcium, phosphorus, and PTH levels) to lower SHPT related mortality. Phosphate binders, vitamin D, and calcimimetics have been reported in the management of calcium and phosphate levels in patients with CKD. In addition, patients are advised to restrict dietary intake of phosphorus by limiting phosphate-rich foods such as beverages, meat, cheese, and dietary products. The Secondary Hyperparathyroidism market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Secondary Hyperparathyroidismmarkettrends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. According to DelveInsight, Secondary Hyperparathyroidism market in 7MM is expected to change in the study period 2017-2030. Click here and get free access to sample pages.